RECRUITING

Sickle Cell Improvement: Enhancing Care in the Emergency Department

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Sickle cell disease (SCD) is an inherited blood disorder affecting approximately 36,000 children in the United States, approximately 90% of whom are Black. The disease is characterized by recurrent, severe pain crises which result in high rates of emergency department visits and hospitalizations, and decreased quality of life. The National Heart, Lung and Blood Institute, as well as the American Society of Hematology, have endorsed pain management guidelines regarding the timeliness of care for children presenting with these acute pain crises. These evidence-based guidelines are infrequently followed, resulting in increased pain and hospitalizations. In additional to other barriers to following the guideline, structural racism has been proposed as a significant contributor and the New England Journal of Medicine recently called for the institution of SCD-specific pain management protocols to combat structural racism and reduce time to opioid administration. The investigators' long-term goal is to improve the care and health outcomes of children with acute painful vaso-occlusive crisis treated in the emergency department. The overall aim of the investigators is to test a care pathway using multifaceted implementation strategies to increase guideline adherent care for children in the emergency department with acute painful vaso-occlusive crisis.

Official Title

Sickle Cell Improvement: Enhancing Care in the Emergency Department

Quick Facts

Study Start:2021-09-01
Study Completion:2027-08-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05373771

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified to 18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * ED visit for uncomplicated pain crisis
  2. * Sickle cell disease
  3. * Receipt of at least one opioid
  1. * Acute chest syndrome
  2. * Fever \> 38.5 in the ED
  3. * priapism
  4. * sickle cell trait

Contacts and Locations

Study Contact

David Brousseau, MD, MS
CONTACT
(302) 651-4000
david.brousseau@nemours.org

Principal Investigator

David Brousseau, MD, MS
PRINCIPAL_INVESTIGATOR
Nemours Children's Health

Study Locations (Sites)

Children's Wisconsin
Milwaukee, Wisconsin, 53226
United States

Collaborators and Investigators

Sponsor: Medical College of Wisconsin

  • David Brousseau, MD, MS, PRINCIPAL_INVESTIGATOR, Nemours Children's Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-09-01
Study Completion Date2027-08-31

Study Record Updates

Study Start Date2021-09-01
Study Completion Date2027-08-31

Terms related to this study

Additional Relevant MeSH Terms

  • Sickle Cell Crisis